Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCTR | P47872 | 9/20 | 1.00 |
| ▸ | SMO | Q99835 | 1/20 | 1.00 |
| ▸ | FLT3 | P36888 | 10/20 | 0.57 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Purmorphamine SCHEMBL1548273 | 1.00 | SCTR (1.00) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075696 | 0.99 | SCTR (0.98) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075697 | 0.98 | SCTR (0.95) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL16367807 | 0.94 | SCTR (0.89) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075700 | 0.87 | SCTR (0.76) | SCTRSMOFLT3 | |
| SCHEMBL14707305 | 0.86 | SCTR (0.76) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL31402481 | 0.86 | SCTR (0.75) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075691 | 0.85 | SCTR (0.74) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075692 | 0.85 | SCTR (0.74) | SCTRSMOFLT3PDGFRA | |
| SCHEMBL14075698 | 0.84 | SCTR (0.72) | SCTRSMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1224 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132374-A1 | Compositions and Methods for Efficient Amplification of Retinal Progenitors Cells | SORBONNE UNIVERSITE (FR) | 2026-05-14 | — | — | US | claimed |
| US-20260115318-A1 | GENE CORRECTION INDUCED NEURAL STEM CELLS USING HUNTINGTIN GENE-SPECIFIC GUIDE RNA, AND CELL THERAPEUTIC AGENT USING THE SAME | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2026-04-30 | — | — | US | claimed |
| EP-3868873-B1 | PRODUCTION METHOD FOR RETINAL TISSUE | RACTHERA CO LTD (JP) | 2026-04-29 | — | — | EP | claimed |
| EP-4728055-A2 | METHODS FOR DIFFERENTIATING DOPAMINERGIC NEURONS FROM STEM CELLS | Aspen Neuroscience, Inc. (US) | 2026-04-22 | — | — | EP | claimed |
| EP-3768222-B1 | REGENERATION OF VITAL TOOTH PULP | UNIV PITTSBURGH COMMONWEALTH SYS HIGHER EDUCATION (US) | 2026-04-22 | — | — | EP | claimed |
| US-12600943-B2 | Innervated organoid compositions and methods of making same | THE UNIVERSITY OF HONG KONG | 2026-04-14 | — | — | US | claimed |
| US-12590954-B2 | Neural stem cell-induced differential medium and induction differentiation method | IREGENE THERAPEUTICS, CO., LTD. (CN) | 2026-03-31 | — | — | US | claimed |
| EP-4711447-A1 | MEDIUM COMPOSITION FOR CULTURING NEUROMUSCULAR ORGANOID AND METHOD FOR PRODUCING NEUROMUSCULAR ORGANOID | Animuscure Inc. (KR) | 2026-03-18 | — | — | EP | claimed |
| US-12565639-B2 | Methods for differentiating dopaminergic neurons from stem cells | ASPEN NEUROSCIENCE, INC. (US) | 2026-03-03 | — | — | US | claimed |
| US-12533383-B2 | Method for producing cell aggregate including glial progenitor cells | KEIO UNIVERSITY (JP) | 2026-01-27 | — | — | US | claimed |
| US-20220112457-A1 | PRODUCTION METHOD FOR NERVE TISSUE | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2022-04-14 | — | — | US | claimed |
| CN-114262686-A | Preparation method and application of oligodendrocyte | 深圳市夏同生物医药科技有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-20220098550-A1 | METHOD FOR MANUFACTURING TELENCEPHALON OR PROGENITOR TISSUE THEREOF | RIKEN (JP) | 2022-03-31 | — | — | US | claimed |
| US-20220090011-A1 | INNERVATED ORGANOID COMPOSITIONS AND METHODS OF MAKING SAME | CHILDREN'S HOSPITAL MEDICAL CENTER | 2022-03-24 | — | — | US | claimed |
| WO-2022060466-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-03-24 | — | — | WO | claimed |
| US-20220087950-A1 | COMPOUNDS, TARGETS AND PATHWAYS FOR MACROPHAGE MODULATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-03-24 | — | — | US | claimed |
| WO-2022037570-A1 | EXPANSION CULTURE MEDIUM AND CULTURE METHOD FOR NEURAL CELLS | 中国科学院动物研究所 | 2022-02-24 | — | — | WO | claimed |
| EP-3303564-B1 | METHODS OF IN VITRO DIFFERENTIATION OF MIDBRAIN DOPAMINE (MDA) NEURONS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2022-02-23 | — | — | EP | claimed |
| EP-3954763-A1 | METHOD FOR PRODUCING ADENOHYPOPHYSIS OR PRECURSOR TISSUE THEREOF | RIKEN (JP) | 2022-02-16 | — | — | EP | claimed |
| CN-108865997-B | Culture medium and culture method for in vitro culture of astrocytes | 华南师范大学 | 2022-02-11 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12533383-B2 | Method for producing cell aggregate including glial progenitor cells | BMP4, WNT3A, BMPR2 | SCTR 1721/4885SMO 11/4885FLT3 3841/4885 |
| US-12600943-B2 | Innervated organoid compositions and methods of making same | GLI2, PAX2, CHRNB2 | SCTR 530/4885SMO 19/4885FLT3 3076/4885 |
| US-20260115318-A1 | GENE CORRECTION INDUCED NEURAL STEM CELLS USING HUNTINGTIN GENE-SPECIFIC GUIDE RNA, AND CELL THERAPEUTIC AGENT USING THE SAME | HTT, NES, NSUN3 | SCTR 4349/4885SMO 1054/4885FLT3 2435/4885 |
| US-20260132374-A1 | Compositions and Methods for Efficient Amplification of Retinal Progenitors Cells | IGF1R, NR2E3, TFEB | SCTR 215/4885SMO 34/4885FLT3 261/4885 |
| US-12590954-B2 | Neural stem cell-induced differential medium and induction differentiation method | SMAD3, SALL4, BMP4 | SCTR 1195/4885SMO 64/4885FLT3 820/4885 |
| US-12565639-B2 | Methods for differentiating dopaminergic neurons from stem cells | GSK3B, WNT3A, GSK3A | SCTR 4042/4885SMO 34/4885FLT3 2523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.